47 related articles for article (PubMed ID: 22018405)
1. Uncertainty and quality of life among men undergoing active surveillance for prostate cancer in the United States and Ireland.
Hegarty JM; Wallace M; Comber H
Am J Mens Health; 2008 Jun; 2(2):133-42. PubMed ID: 19477777
[TBL] [Abstract][Full Text] [Related]
2. Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance.
Roemeling S; Roobol MJ; Postma R; Gosselaar C; van der Kwast TH; Bangma CH; Schröder FH
Eur Urol; 2006 Sep; 50(3):475-82. PubMed ID: 16713065
[TBL] [Abstract][Full Text] [Related]
3. Active surveillance for the management of prostate cancer in a contemporary cohort.
Dall'Era MA; Konety BR; Cowan JE; Shinohara K; Stauf F; Cooperberg MR; Meng MV; Kane CJ; Perez N; Master VA; Carroll PR
Cancer; 2008 Jun; 112(12):2664-70. PubMed ID: 18433013
[TBL] [Abstract][Full Text] [Related]
4. Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristics.
Krakowsky Y; Loblaw A; Klotz L
J Urol; 2010 Jul; 184(1):131-5. PubMed ID: 20478589
[TBL] [Abstract][Full Text] [Related]
5. Active surveillance as a treatment option for prostate cancer.
Hegarty J; Bailey DE
Semin Oncol Nurs; 2011 Nov; 27(4):260-6. PubMed ID: 22018405
[TBL] [Abstract][Full Text] [Related]
6. [Active surveillance for screen-detected prostate cancer - a strategy for the future?].
Weissbach L; Schaefer C
Aktuelle Urol; 2010 Jul; 41(4):239-44. PubMed ID: 20661840
[TBL] [Abstract][Full Text] [Related]
7. Active surveillance: pitfalls to consider.
Ercole B; Parekh DJ
Arch Esp Urol; 2011 Oct; 64(8):695-702. PubMed ID: 22052752
[TBL] [Abstract][Full Text] [Related]
8. Active surveillance for low-risk prostate cancer: selection of patients and predictors of progression.
Dall'Era MA; Konety BR
Nat Clin Pract Urol; 2008 May; 5(5):277-83. PubMed ID: 18285752
[TBL] [Abstract][Full Text] [Related]
9. Active surveillance with selective delayed intervention for favorable risk prostate cancer: clinical experience and a 'number needed to treat' analysis.
Klotz LH; Nam RK
Can J Urol; 2006 Feb; 13 Suppl 1():48-55. PubMed ID: 16526983
[TBL] [Abstract][Full Text] [Related]
10. Active surveillance for prostate cancer: progress and promise.
Cooperberg MR; Carroll PR; Klotz L
J Clin Oncol; 2011 Sep; 29(27):3669-76. PubMed ID: 21825257
[TBL] [Abstract][Full Text] [Related]
11. The prostate-specific antigen screening conundrum: examining the evidence.
O'Rourke ME
Semin Oncol Nurs; 2011 Nov; 27(4):251-9. PubMed ID: 22018404
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
